2016 US lymphoid malignancy statistics by World Health Organization subtypes

CA Cancer Journal for Clinicians

Volumn 66, Issue 6, 2016, Pages 443-459

  Teras, Lauren R ^a   DeSantis, Carol E ^a   Cerhan, James R ^b   Morton, Lindsay M ^c   Jemal, Ahmedin ^a   Flowers, Christopher R ^d  

^a AMERICAN CANCER SOCIETY   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic lymphocytic leukemia; epidemiology; Hodgkin disease; multiple myeloma; non Hodgkin lymphoma

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BODY MASS; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CLINICAL PRACTICE; CYTOGENETICS; ENERGY BALANCE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; IMMUNOBLASTIC LYMPHOMA; IMMUNOPHENOTYPING; INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY; LARGE CELL LYMPHOMA; LIFESTYLE; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; PERIPHERAL T CELL LYMPHOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SURVIVAL RATE; T CELL LYMPHOMA; UNITED STATES; WALDENSTROEM MACROGLOBULINEMIA; WORLD HEALTH ORGANIZATION;

EID: 84987643710     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21357     Document Type: Article

References (71)

1. Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010;10:414-423.
2. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions [serial online]. Blood. 2010;116:e90-e98.
3. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monog. 2014;2014:130-144.
4. Li Y, Wang Y, Wang Z, Yi D, Ma S. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39:8-13.
5. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002;94:2015-2023.
6. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer. 2010;126:1732-1739.
7. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.
8. Glaser SL, Clarke CA, Keegan TH, Chang ET, Weisenburger DD. Time trends in rates of Hodgkin lymphoma histologic subtypes: true incidence changes or evolving diagnostic practice? Cancer Epidemiol Biomarkers Prevent. 2015;24:1474-1488.
9. Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States [published online ahead of print January 25, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.635540.
10. Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: subtype analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575-1584.
11. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
12. Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prevent. 2013;22:1069-1078.
13. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790-795.
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database, North American Association of Central Cancer Registries (NAACCR) Incidence-Cancer in North America (CiNA) Analytic File, 2001–2012. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 1st ed. Lyon, France: IARC Press; 2001.
16. Total U.S.Cancer InstituteDCCPSSurveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-0000 varying) - Linked To County Attributes -, 1969-0000 Counties, National, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
17. Swerdlow S, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
18. Steven H, Swerdlow EC, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
19. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.
20. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
21. Surveillance Research Program, National Cancer Institute. SEER*Stat Software, version 8.2.1. Bethesda, MD: National Cancer Institute; 2015.
22. National Cancer Institute. Joinpoint Regression Program, version 4.2.0.2. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2015.
23. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
24. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2014 Submission (2000-2012) -Linked To County Attributes-Total US, 1969–2013 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
25. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
26. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year. Cancer. 2012;118:1100-1109.
27. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83-103.
28. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus. A Review of Human Carcinogens. Part B: Biological Agents. Volume 100B. Lyon, France: IARC Press; 2009.
29. Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S27-S32.
30. Linet MS, Kim KP, Rajaraman P. Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr Radiol. 2009;39(suppl 1):S4-S26.
31. Landrigan PJ, Goldman LR. Children's vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy. Health Aff. 2011;30:842-850.
32. Skibola CF, Slager SL, Berndt SI, et al. Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:125-129.
33. Chen J, Zhu B, Chen J, Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 2013;32:414-419.
34. Burmeister T, Bartels G, Groger D, et al. Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group. Hematologica. 2014;99:e23-25.
35. Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36:868-875.
36. Sampson JN, Wheeler WA, Yeager M, et al. Analysis of heritability and shared heritability based on genome-wide association studies for 13 cancer types [serial online]. J Natl Cancer Inst. 2015;107:djv279.
37. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126:2265-2273.
38. Berndt SI, Camp NJ, Skibola CF, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia [serial online]. Nat Commun. 2016;7:10933.
39. Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin. 2003;53:245-255.
40. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma. J Natl Cancer Inst Monogr. 2014;2014:41-51.
41. Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166:667-676.
42. Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120:40-61.
43. Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014;46:1233-1238.
44. Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma. J Natl Cancer Inst Monogr. 2014;2014:15-25.
45. Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33:2963-2974.
46. Boerma E, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans J. Gender and age-related differences in Burkitt lymphoma—epidemiological and clinical data from the Netherlands. Eur J Cancer. 2004;40:2781-2787.
47. Linet MS, Vajdic CM, Morton LM, et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma. J Natl Cancer Inst Monogr. 2014;2014:26-40.
48. Bracci PM, Benavente Y, Turner JJ, et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma. J Natl Cancer Inst Monogr. 2014;2014:52-65.
49. Aschebrook-Kilfoy B, Cocco P, La Vecchia C, et al. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sezary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:98-105.
50. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990;50:3605-3609.
51. Monnereau A, Slager SL, Hughes AM, et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:115-124.
52. Centers for Disease Control and Prevention (CDC). HIV Surveillance Report, 2014. Volume 26. Bethesda, MD: Centers for Disease Control and Prevention; 2015. cdc.gov/hiv/library/reports/surveillance/. Accessed March 28, 2016.
53. Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer. 2009;53:366-370.
54. Ahmed SA, Hissong B, Verthelyi D, Donner K, Becker K, Karpuzoglu-Sahin E. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect. 1999;107(suppl 5):681-681.
55. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
56. Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 2003;22:87-93.
57. Wilkinson JD, Fleming LE, MacKinnon J, et al. Lymphoma and lymphoid leukemia incidence in Florida children. Cancer. 2001;91:1402-1408.
58. Perez-Saldivar ML, Fajardo-Gutierrez A, Bernaldez-Rios R, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology [serial online]. BMC Cancer. 2011;11:355.
59. Mejia-Arangure J, Bonilla M, Lorenzana R, et al. Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data [serial online]. BMC Cancer. 2005;5:33.
60. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975–2012, based on Nov 2014 SEER data submission. Bethesda, MD: National Cancer Institute; 2015.
61. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4:161-168.
62. Teras LR, Kitahara CM, Birmann BM, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166:667-676.
63. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
64. Call TG, Norman AD, Hanson CA, et al. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer. 2014;120:2000-2005.
65. Jamal A, Homa DM, O'Connor E, et al. Current cigarette smoking among adults—United States, 2005-2014. MMWR Morb Moral Wkly Rep. 2015;64:1233-1240.
66. Wang SS, Flowers CR, Kadin ME, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:66-75.
67. Diver WR, Patel AV, Thun MJ, Teras LR, Gapstur SM. The association between cigarette smoking and non-Hodgkin lymphoid neoplasms in a large US cohort study. Cancer Causes Control. 2012;23:1231-1240.
68. Diver WR, Teras LR, Gaudet MM, Gapstur SM. Exposure to environmental tobacco smoke and risk of non-Hodgkin lymphoma in nonsmoking men and women. Am J Epidemiol. 2014;179:987-995.
69. Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91:90-100.
70. Flowers CR, Pro B. Racial differences in chronic lymphocytic leukemia. Cancer. 2013;119:3593-3595.
71. Modiano MR, Villar-Werstler P, Crowley J, Salmon SE. Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol. 1996;14:974-977.